Aiming to protect its blockbuster psoriasis drug Cosentyx, Novartis slapped Johnson & Johnson with a lawsuit claiming it's using "cherry-picked" safety stats to promote its rival therapy Tremfya. And it's demanding an injunction to stop those promos, stat.
